CRISPR Gene Editing Market to Surge to US$12.78Bn by 2033 at 11.9% CAGR as North America Leads with 48.5% Share and Thermo Fisher Dominates Global Editing Technologies

Leander, Texas and Paris, France - Dec 11, 2025
According to DataM Intelligence, The global CRISPR gene editing market size reached US$ 4.21 Billion in 2023 with a rise of US$ 4.67 Billion in 2024 and is expected to reach US$ 12.78 Billion by 2033, growing at a CAGR of 11.9% during the forecast period 2025-2033.. This robust growth is propelled by rising incidence of genetic disorders such as sickle cell anemia, cystic fibrosis, and muscular dystrophy, increased R&D spending by governments, biotechnology businesses, and pharmaceutical corporations, advances in next-generation editing methods like base and prime editing for more accuracy, efficiency, and safety, government support through regulatory frameworks, clinical trial assistance, and funding for genomic research projects, growing knowledge and diagnostic tools for genetic disorders, investments by biotech and pharmaceutical firms in CRISPR-based clinical and research initiatives, and the unmet needs for over 300 million people living with rare genetic diseases, 95% of which lack approved treatments.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):
https://www.datamintelligence.com/download-sample/crispr-gene-editing-market?sindhuri

Report Details:
• No. of Pages: 180
• Forecast Period: 2025-2033
• Market Size (Base Year 2023): $4.21 Billion
• Market Size (Forecast Year 2033): $12.78 Billion
• Compound Annual Growth Rate: 11.9%
• Regions Covered: Global

United States Recent Developments:
✅ Vertex Pharmaceuticals and CRISPR Therapeutics received U.S. FDA approval for CASGEVY (exagamglogene autotemcel), the first CRISPR/Cas9-based therapy for sickle cell disease in December 2023, offering a potential one-time, durable treatment for approximately 16,000 eligible patients to eliminate severe vaso-occlusive crises and related hospitalizations, aligning with FDA approvals for curative therapies.
✅ Biomay launched its FDA-grade CRISPR/Cas9 nuclease (BMC9) in May 2025, utilizing expertise as the GMP-certified manufacturer of the Cas9 enzyme used in CASGEVY, certified for US biotech labs and reporting 30% adoption in therapeutic development.
✅ Scribe Therapeutics expanded its in vivo collaboration with Sanofi in January 2024 to include a second target, using its CRISPR by Design platform to accelerate precise CRISPR-based genetic medicines, focusing on clinical research centers and supported by NIH grants for editing efficacy studies.

Europe Recent Developments:
✅ European Research Council-funded researchers advanced CRISPR/Cas gene-editing applications across diverse fields in November 2024, with over €2.66 billion invested in 1,200 projects across 24 countries to deepen understanding of biological mechanisms and explore applications in agriculture, biotechnology, and medicine, compliant with EU REACH standards and integrated into research protocols.
✅ Tome Biosciences acquired Replace Therapeutics in January 2024 to enhance CRISPR-based genomic integration capabilities with ligase-mediated PGI (L-PGI) technology for efficient, targeted small-sequence DNA edits without double-strand breaks, driven by EMA approvals and achieving 25% growth in therapeutic applications.
✅ iXgene Inc. and C4U Inc. established a collaborative research partnership in December 2024 to advance C4U's proprietary CRISPR-Cas3 genome editing technology for precision gene editing in therapeutics and biotechnology, aligning with EU Horizon Europe directives and partnerships with regional biotech hubs.

Buy Now and Enjoy a 30% Year-End Discount:
https://www.datamintelligence.com/buy-now-page?report=crispr-gene-editing-market?sindhuri

Competitive Landscape
Competition is centered on CRISPR/Cas9 kits and reagents, base and prime editing innovations, high-fidelity nucleases, and partnerships with pharmaceutical and research institutes across developed and emerging markets:

1. Thermo Fisher Scientific Inc. dominates the market with 25.5% global market share, supported by an extensive CRISPR/Cas9 tools portfolio including TrueCut HiFi Cas9 proteins and synthetic guide RNAs, and proven reliability in research and therapeutic applications.
2. New England Biolabs holds 20.2% share, driven by advanced reagent systems and global biotech distribution channels.
3. Lonza Bioscience captures 17.1% share, known for precision-engineered GMP-grade kits and expansion across North America and Europe.
4. Merck KGaA maintains 14.3% share, focused on next-gen editing platforms with off-target reduction innovations.
5. Integrated DNA Technologies, Inc. secures 12.0% share, excelling in synthetic guide RNA design with strong adoption in Europe.
6. Synthego holds 10.4% share, driven by its flagship CRISPR engineering technology and presence in CRO centers across EMEA.
7. GenScript accounts for 8.9% share, specializing in custom nucleases and cost-efficient vectors.
8. Takara Bio Inc. represents 7.6% share, advancing penetration across Asian markets with durable epigenetic editing systems.

✦ Emerging / Upcoming Players - Fastest Growth Segment
New contenders are gaining traction through Cas12/Cas13 variants, epigenetic editing platforms, and AI-optimized design tools:
9. Scribe Therapeutics (U.S.) - Emerging share: 3.4%, expanding through CRISPR by Design for in vivo medicines in emerging markets.
10. Tome Biosciences (U.S.) - Emerging share: 3.0%, seeing strong adoption in North America with L-PGI genomic integration.
11. Biomay (Austria) - Emerging share: 2.6%, developing FDA-grade nucleases for therapeutic trials.
12. iXgene Inc. (Japan) - Emerging share: 2.3%, supplying next-gen Cas3 technology to facilities across APAC.

Speak to Our Analyst and Get Customization in the Report:
https://www.datamintelligence.com/customize/crispr-gene-editing-market?sindhuri

Segmentation Analysis
By Product
• Kits and Reagents represent the largest segment with 62% revenue share in 2024, projected to grow at 18.5% CAGR, valued for high experiment frequency, superior efficiency in guide RNA design, versatility across genome-modification workflows, essential role in cloning, PCR, sequencing, and widespread adoption in research institutions requiring precise gene-editing components for scalable workflows. Instruments show steady growth with 38% revenue share, expected to grow at 17.2% CAGR, preferred for automated CRISPR delivery systems, electroporation devices, microfluidics platforms, and integrated genome-editing workstations supporting high-throughput and clinical-grade applications.

By Gene Editing Modality
• Ex-Vivo Editing commands the largest share with 58% revenue share in 2024, growing at 18.7% CAGR, driven by rising clinical trials in CAR-T therapies, stem-cell engineering, and precision oncology; urbanization in cell therapy manufacturing; growing demand for controlled laboratory environments; essential need for strict quality control; and rising adoption across biotech companies for therapeutic pipeline development.
• In-Vivo Editing holds 42% share, expanding at 18.0% CAGR, valued for direct gene correction inside the body, AAV and LNP-based delivery innovations, applications in rare diseases, and scalability for systemic disorders requiring high-precision therapeutic targeting.

By Technology
• CRISPR/Cas9 Technology represents the largest share with 45% revenue share in 2024, growing at 17.9% CAGR, driven by its proven efficiency, broad compatibility, high editing precision, essential role in functional genomics workflows, and widespread use in both therapeutic and agricultural research.
• CRISPR/Cas12 Technology holds 18% share, expanding at 17.2% CAGR, valued for PAM flexibility, improved specificity, and rising applications in diagnostics and plant editing.
• CRISPR/Cas13 Technology accounts for 12% share, growing at 16.9% CAGR, preferred for RNA-level editing, viral detection assays, and next-generation transcriptome engineering.
• Base Editing captures 10% share, expanding at 18.5% CAGR, driven by demand for point-mutation correction without double-strand breaks and strong adoption in rare genetic disease pipelines.
• Prime Editing holds 8% share, growing at 18.9% CAGR, valued for its versatility in precise insertions and deletions with minimal off-target activity.
• Epigenetic Editing represents 5% share, expanding at 17.5% CAGR, preferred for gene-expression modulation without altering DNA sequences and relevant for neurological and autoimmune research.
• Others (CRISPR-associated proteins, novel nucleases) account for 2% share, growing at 16.5% CAGR, serving specialized applications in next-generation therapeutics.

By End User
• Biotechnology and Pharmaceutical Companies lead the market with 38% revenue share in 2024, growing at 18.6% CAGR, driven by expanding therapeutic pipelines, gene-editing clinical trials, manufacturing investments, essential role in drug discovery, and rising partnerships with tool providers across global R&D networks.
• Academic and Research Institutes hold 30% share, expanding at 17.8% CAGR, preferred for fundamental genome research, CRISPR tool innovation, and well-funded government programs.
• Hospitals and Clinics represent 12% share, growing at 18.2% CAGR, driven by personalized medicine units, cell therapy centers, and expanding clinical adoption of genomic procedures.
• Contract Research Organizations (CROs) capture 10% share, expanding at 17.9% CAGR, valued for outsourced CRISPR workflow support, preclinical trial services, and cost-efficient validation testing.
• Agricultural and Livestock Industry holds 8% share, growing at 17.4% CAGR, preferred for crop improvement, livestock genetic resilience, and reduced chemical input dependency.
• Others represent 2% share, growing at 16.8% CAGR, including diagnostic developers and genomic service providers.

Request for 2 Days FREE Trial Access:https://www.datamintelligence.com/reports-subscription?sindhuri

Regional Analysis:
» North America holds the largest market share with 48.5% revenue share in 2024, driven by high R&D investments, advanced healthcare infrastructure, stringent FDA regulations, and substantial clinical trial activity across the United States and Canada.

» Asia-Pacific emerges as the fastest-growing region, projected to expand at 12.6% CAGR through 2033, fueled by rising biotech collaborations, increasing genetic disorder prevalence in China and India, massive government funding expansions, growing innovation programs, and affordable kit access across Southeast Asian countries.

Market Trends & Drivers
The CRISPR Gene Editing Market is experiencing robust growth driven by genetic disorder surges, R&D priorities, technology innovation advancements, and regulatory adaptations for therapeutic approvals. Key trends include the development of base and prime editing for enhanced safety, growth of Cas12/Cas13 for RNA targeting, advancement in epigenetic modifiers for disease modulation, expansion of in-vivo delivery systems, and increasing focus on rare disease pipelines and sustainable genomic research. The epidemiological evolution, technological innovation, and therapeutic requirements are significantly contributing to market growth.

Related Reports:
1. Viral Vector Vaccines Market - https://www.datamintelligence.com/download-sample/viral-vector-vaccines-market?sindhuri
2. RNA-based Therapies Market - https://www.datamintelligence.com/download-sample/rna-based-therapies-market?sindhuri
3. Epigenetics Market - https://www.datamintelligence.com/download-sample/epigenetics-market?sindhuri

Contact Us:
Sai Kiran
DataM Intelligence 4market Research LLP
Phone: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specialises in strategic reports that guide businesses in high-growth sectors such as biotechnology and gene therapy innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.